The organizers of the III All-Russia GMP-conference, held in Kazan (Russia) for three days, are determined to provide environment for a bilateral dialogue, new business contacts, mastering new practices, and many other ambitious solutions.
On Day One – during the panel discussion devoted to the Pharmaceutical industry of the Future. Government and business perspectives. The participants touched on the most global issues including interaction of key players in the pharmaceutical market. The panel was honored by officials from the Russian Ministry of Industry and Trade, the Russian Health Ministry, the State Institute of Drugs and Good Practices; and business circles from BIOCAD, Nanolek, Teva, GEROFARM, MSD, Merck Biopharma Russia & CIS, as well as a representative of Pharmaceutical Innovations (Association of Pharmaceutical Companies). The audience expressed their understanding of what the industry should be like in ten years. The Ministry of Industry and Trade is actively working on Pharma-2030 strategy, and the conference has become another tool to fine-tune this document of utmost importance for Russian pharmaceutical industry.
Alexey Alekhin, Head of the Department for Pharmaceutical and Medical Industry Development of the Ministry of Industry and Trade of the Russian Federation, commented:
“On behalf of the Russian Ministry of Industry and Trade, I would like to thank all those who took part in drafting the strategy. We held a series of meetings and have developed a joint position of industry representatives, highlighted the milestones that should be visible in the development strategy for pharmaceutical industry. I would like to draw your attention to the fact that since we are in charge of evolving production competencies through 2030, the whole document is about industry. And there no doubt that as an industry we need to rely on market laws.”
Education and human resources simply could not be left out of the discussed issues. Leaders of the prominent academic institutions, i.e. the St. Petersburg State Chemical and Pharmaceutical University, the Kazan Federal University, the Scientific Centre for Expert Evaluation of Medicinal Products shared their professional expertise in that respect. Personnel training now requires additional investments that universities and colleges cannot always accommodate. Challenges of globalization and digitalization of economy, growing appeal of IT-technologies make education in the industry impossible without modeling systems.
The delegates also called on the authors of the strategy to pay attention to success stories of foreign product localization. Representatives of foreign companies – Merck Biopharma Russia & CIS and Teva – shared their insights of making Russian market a priority for investments.
“The strategy should be aimed at finding solutions to secure an innovative breakthrough for Russian pharmaceutical industry. Russia should become a country where innovations from all over the world are striving – it concerns molecules that are already being developed in the Russian Federation and those that are being developed abroad, but sooner or later they will find themselves on the Russian market and maybe through the localization mechanism,” said Andrey Kolesnikov, TEVA CEO for GR and Market Access in Russia and Eurasia.